Phase II study of cetuximab plus FOLFIRI as first-line treatment in patients with unresectable/metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma (FOLCETUX study) : Preliminary results

• PINTO C

収録刊行物

• Proc ASCO, 2006

  Proc ASCO, 2006 2006

詳細情報

• CRID: 1570854175364370816
• NII論文ID: 10018886583
• データソース種別:
  • CiNii Articles